CA2501132A1 - Cyclodextrin-based materials, compositions and uses related thereto - Google Patents

Cyclodextrin-based materials, compositions and uses related thereto Download PDF

Info

Publication number
CA2501132A1
CA2501132A1 CA002501132A CA2501132A CA2501132A1 CA 2501132 A1 CA2501132 A1 CA 2501132A1 CA 002501132 A CA002501132 A CA 002501132A CA 2501132 A CA2501132 A CA 2501132A CA 2501132 A1 CA2501132 A1 CA 2501132A1
Authority
CA
Canada
Prior art keywords
polymer
inclusion
cyclodextrin
matrix
polymer composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002501132A
Other languages
English (en)
French (fr)
Inventor
Nathalie C. Bellocq
Mark E. Davis
Suzie Hwang Pun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calando Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2501132A1 publication Critical patent/CA2501132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626—Liposomes, micelles, vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
CA002501132A 2002-10-09 2003-10-08 Cyclodextrin-based materials, compositions and uses related thereto Abandoned CA2501132A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41737302P 2002-10-09 2002-10-09
US60/417,373 2002-10-09
PCT/US2003/031991 WO2004032862A2 (en) 2002-10-09 2003-10-08 Cyclodextrin-based materials, compositions and uses related thereto

Publications (1)

Publication Number Publication Date
CA2501132A1 true CA2501132A1 (en) 2004-04-22

Family

ID=32094010

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002501132A Abandoned CA2501132A1 (en) 2002-10-09 2003-10-08 Cyclodextrin-based materials, compositions and uses related thereto

Country Status (13)

Country Link
US (3) US8357377B2 (enExample)
EP (1) EP1549269A4 (enExample)
JP (1) JP4602085B2 (enExample)
KR (1) KR20050051686A (enExample)
CN (1) CN1717209A (enExample)
AU (1) AU2003295344B2 (enExample)
BR (1) BR0315198A (enExample)
CA (1) CA2501132A1 (enExample)
MX (1) MXPA05003591A (enExample)
RU (1) RU2005114007A (enExample)
TW (1) TW200423960A (enExample)
WO (1) WO2004032862A2 (enExample)
ZA (1) ZA200502754B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
WO2004032862A2 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
BRPI0418276B8 (pt) 2003-12-31 2021-05-25 Cydex Pharmaceuticals Inc formulação líquida inalável compreeendendo budesonida
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
ATE446581T1 (de) * 2004-03-12 2009-11-15 Trinity College Dublin Magnetoresistives medium
MXPA06015148A (es) * 2004-07-01 2007-08-21 Netherlands Cancer Inst Combinacion que comprende un inhibidor de bcrp y 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida.
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
WO2006115211A1 (ja) * 2005-04-25 2006-11-02 Kaneka Corporation シクロデキストリン含有ポリエステル系重合体及びその製造方法
WO2007009265A1 (en) * 2005-07-22 2007-01-25 The Governors Of The University Of Alberta Tec Edmonton NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
JP2007211060A (ja) * 2006-02-07 2007-08-23 Japan Advanced Institute Of Science & Technology Hokuriku 超分子ポリマー及びその合成方法
WO2007095341A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Sterilization of corticosteroids with reduced mass loss
KR100809046B1 (ko) * 2006-03-10 2008-03-03 가톨릭대학교 산학협력단 풀루란을 가진 나노자가응집체 및 이의 이용방법
US20080027212A1 (en) * 2006-06-28 2008-01-31 Skinner Keith K Methods and compositions for improved uptake of biological molecules
JP2010514679A (ja) * 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2130023B1 (en) 2007-03-15 2015-05-06 Ventana Medical Systems, Inc. Stabilized hematoxylin
US8343995B2 (en) 2007-04-27 2013-01-01 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
EP2170054A4 (en) * 2007-06-28 2012-08-08 Capsutech Ltd TARGETING CONJUGATES WITH ACTIVE SUBSTANCES ENCAPLED IN CYCLODEXTRIN POLYMERS
ITMI20071321A1 (it) * 2007-07-04 2009-01-05 Sea Marconi Technologies Di Va Nanospugne a base di ciclodestrine come veicolo per farmaci antitumorali
WO2009123764A2 (en) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010088286A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088282A1 (en) * 2009-01-30 2010-08-05 Rgo Biosciences Llc Nucleic acid binding assays
WO2010099466A2 (en) * 2009-02-26 2010-09-02 The Regents Of The University Of California A supramolecular approach for preparation of size controllable nanoparticles
CN102625658B (zh) 2009-05-13 2015-01-28 锡德克斯药物公司 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
PL2434886T3 (pl) 2009-05-29 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania
US10045937B2 (en) * 2009-06-03 2018-08-14 Case Western Reserve University Therapeutic agent delivery system and method
US9468650B2 (en) 2009-09-16 2016-10-18 Duke University Inhibition of endosomal toll-like receptor activation
MX337393B (es) * 2009-11-18 2016-03-02 Nektar Therapeutics Forma salina de un conjugado de polímero-farmaco con multiples brazos.
EP2503888A4 (en) 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CN103037903A (zh) * 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
WO2012044832A1 (en) * 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
CA2816322A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
WO2013013245A2 (en) * 2011-07-21 2013-01-24 The Regents Of The University Of California Catalytic delivery nanoubstrates (cdns) for highly efficient delivery of biomolecules
CN103289075B (zh) * 2012-02-22 2016-01-20 天津键凯科技有限公司 聚乙二醇与纳洛酮的结合物及其药物组合物和应用
FR2989001B1 (fr) * 2012-04-06 2017-07-21 Centre Nat Rech Scient Microparticules et nanoparticules constituees de polysaccharides hydrophobises et d'une alpha-cyclodextrine
WO2013158710A2 (en) 2012-04-18 2013-10-24 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP6445453B2 (ja) * 2012-11-28 2018-12-26 ビクトリア リンク リミテッド 樹状コア化合物
EP2956122B1 (en) * 2013-02-15 2021-01-27 The Regents of the University of California Supramolecular magnetic nanoparticles
WO2014134284A1 (en) 2013-02-27 2014-09-04 Crayola Llc Rinsable inks and methods of making the same
DE102013021060A1 (de) * 2013-12-18 2015-06-18 Rathor Ag Verfahren zur Abtrennung von Monomeren aus isocyanathaltigen Prepolymeren
JP6300926B2 (ja) * 2014-07-08 2018-03-28 国立大学法人大阪大学 自己修復性を有する高分子材料及びその製造方法
GB2540914B (en) 2014-07-09 2021-11-24 Halliburton Energy Services Inc Treatment fluids for reducing subterranean formation damage
CN107427003B (zh) 2015-02-02 2023-01-31 梅制药公司 联合治疗
MX370604B (es) 2015-06-19 2019-12-18 Univ Queensland Composicion.
CN105999289B (zh) * 2016-04-01 2018-11-20 南开大学 一种二元超两亲性纳米粒子溶液及其制备方法和应用
CN106349396A (zh) * 2016-08-26 2017-01-25 湖南尔康制药股份有限公司 一种具有超声敏感性的交联淀粉
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
CN112011040B (zh) * 2020-07-20 2021-08-17 广州医科大学 一种多重纳米传递系统及其制备方法
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
US20240115709A1 (en) * 2021-02-25 2024-04-11 Noble Panacea Labs, Inc. Assembly of organic supramolecular vessels for controlled drug release
WO2026085322A1 (en) 2024-10-18 2026-04-23 Aardvark Therapeutics Inc. Isoflavonoid formulations and methods of use

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390479A (en) 1973-09-05 1975-04-16 I Orch Sinteza Akademii Nauk L Pharmaceutical composition for treatment of parkinsonism
DE2842862A1 (de) 1978-10-02 1980-04-10 Boehringer Mannheim Gmbh Verfahren zur bestimmung von ionen, polaren und/oder lipophilen substanzen in fluessigkeiten
CH663951A5 (fr) * 1984-10-10 1988-01-29 Nestle Sa Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant.
US4841081A (en) 1985-10-16 1989-06-20 Osaka Soda Co., Ltd. Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound
GB2197720A (en) 1986-11-20 1988-05-25 Nat Res Dev Immobilisation of polynucleotides
WO1988010297A1 (en) 1987-06-17 1988-12-29 Princess Margaret Children's Medical Research Foun Cloning of mite allergens
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
US4887778A (en) 1988-06-01 1989-12-19 Universal Instruments Corporation Feeder drive assembly and replaceable section for tape supplying and cover peeling
HU200913B (en) 1988-07-28 1990-09-28 Ciklodextrin Kutato Fejlesztoe Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility
US5098793A (en) * 1988-09-29 1992-03-24 Uop Cyclodextrin films on solid substrates
US5139687A (en) 1990-05-09 1992-08-18 The Proctor & Gamble Company Non-destructive carriers for cyclodextrin complexes
JPH0425505A (ja) 1990-05-21 1992-01-29 Toppan Printing Co Ltd シクロデキストリンポリマー及びシクロデキストリン膜の製造方法
KR927003647A (ko) * 1990-11-30 1992-12-18 돕빵 인사쯔 가부시끼가이샤 시클로덱스트린유도체 및 시클로덱스트린 고정화 폴리머의 제조방법
JP2976154B2 (ja) * 1991-11-27 1999-11-10 コニカ株式会社 ハロゲン化銀写真感光材料用固形処理剤
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
HU218280B (en) 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5728804A (en) 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
US6667293B1 (en) 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
DE19629494A1 (de) * 1996-07-09 1998-01-15 Schering Ag Pseudopolyrotaxane
US5844030A (en) 1996-07-09 1998-12-01 Andros; Nicholas Charged ion cleaning devices and cleaning system
EP1003555A1 (en) 1997-04-23 2000-05-31 The University of Otago Controlled release of ophthalmic compositions
JPH11100401A (ja) 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
ATE347911T1 (de) 1997-09-15 2007-01-15 Genetic Immunity Llc Zusammensetzungen für die zufuhr von genen an antigen-präsentierende zellen der haut
IT1298732B1 (it) 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
DE69935526T2 (de) 1998-12-04 2007-11-22 California Institute Of Technology, Pasadena Supramolekulare komplexe enthaltende arzneimittel
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
JP2003501440A (ja) 1999-06-07 2003-01-14 マイラス コーポレーション 反応活性なジスルフィド結合を含む化合物
DK1102785T3 (da) 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
WO2001037665A1 (en) 1999-11-29 2001-05-31 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
AU2001279164A1 (en) 2000-08-01 2002-02-13 Oregon Health And Science University Mammalian dna binding membrane-associated protein-encoding gene and uses
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
EP2277551B1 (en) * 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
WO2004032862A2 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery

Also Published As

Publication number Publication date
KR20050051686A (ko) 2005-06-01
WO2004032862A2 (en) 2004-04-22
JP2006513992A (ja) 2006-04-27
US20040109888A1 (en) 2004-06-10
US20140199370A1 (en) 2014-07-17
ZA200502754B (en) 2006-09-27
TW200423960A (en) 2004-11-16
CN1717209A (zh) 2006-01-04
RU2005114007A (ru) 2005-10-10
WO2004032862A3 (en) 2004-07-01
BR0315198A (pt) 2005-08-30
EP1549269A4 (en) 2010-10-06
US8357377B2 (en) 2013-01-22
MXPA05003591A (es) 2005-09-30
EP1549269A2 (en) 2005-07-06
AU2003295344A1 (en) 2004-05-04
AU2003295344B2 (en) 2008-01-31
JP4602085B2 (ja) 2010-12-22
US20130315980A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
AU2003295344B2 (en) Cyclodextrin-based materials, compositions and uses related thereto
Kim et al. MMPs-responsive release of DNA from electrospun nanofibrous matrix for local gene therapy: in vitro and in vivo evaluation
Zhong et al. Hydrogels for RNA delivery
US10828398B2 (en) Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methods for their use
Kharkar et al. Thiol–ene click hydrogels for therapeutic delivery
DE69925361T2 (de) Vernetzbare macromere, die eine initiatorgruppe tragen
Kulkarni et al. Emerging role of injectable dipeptide hydrogels in biomedical applications
US20210023221A1 (en) Conductive polymer graphene oxide composite materials
AU2007301693B2 (en) Polymer
CN102573944A (zh) 原位成型水凝胶及其生物医学用途
Lin et al. Redox-responsive hydrogels with decoupled initial stiffness and degradation
CN103083223A (zh) 半乳糖修饰的巯基化壳聚糖季铵盐纳米粒及其制备方法和应用
Newman et al. Multivalent presentation of peptide targeting groups alters polymer biodistribution to target tissues
Wang et al. Nanoparticle-hydrogel systems containing platensimycin for local treatment of methicillin-resistant staphylococcus aureus infection
Lam et al. Biodegradable and pH-responsive amphiphilic poly (succinimide) derivatives for triggered release of antibiotics for management of infected wounds
Wei et al. Straightforward access to glycosylated, acid sensitive nanogels by host–guest interactions with sugar-modified pillar [5] arenes
Lee et al. Enzyme free cell detachment using pH-responsive poly (amino ester) for tissue regeneration
Scott et al. Modular poly (ethylene glycol) scaffolds provide the ability to decouple the effects of stiffness and protein concentration on PC12 cells
Kaur et al. Selective cell adhesion on peptide–polymer electrospun fiber mats
Gupta Smart Systems in Biotechnology
Jiang et al. Nanoparticle-programmed surface for drug release and cell regulation via reversible hybridization reaction
Minden-Birkenmaier et al. Electrospun systems for drug delivery
US20150216993A1 (en) Multifunctional small molecules
Sahoo et al. Histidine-based reduction-sensitive star-polymer inclusion complex as a potential DNA carrier: biophysical studies using time-resolved fluorescence as an important tool
An et al. Bioreducible crosslinked cationic nanopolyplexes from clickable polyethylenimines enabling robust cancer gene therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued